Search Result

Results for "

specific inhibition

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (2) AIM2 (1) AMPK (1) Androgen Receptor (1) Apoptosis (1) Autophagy (4) Bacterial (1) Btk (1) Calcium Channel (3) Caspase (1) CD38 (2) CDK (2) Chloride Channel (1) COX (1) CXCR (1) Deubiquitinase (1) DNA/RNA Synthesis (4) DYRK (1) Epigenetic Reader Domain (1) ERK (1) FLAP (1) Fungal (1) HBV (1) HDAC (1) Histone Demethylase (5) HIV (2) Isocitrate Dehydrogenase (IDH) (2) Kinesin (1) MicroRNA (1) MyD88 (1) Neuropeptide Y Receptor (1) NF-κB (1) NOD-like Receptor (NLR) (2) Notch (1) p38 MAPK (3) Parasite (3) Phosphatase (1) Phosphodiesterase (PDE) (1) PKA (2) PKC (3) Progesterone Receptor (1) PROTACs (2) Pyruvate Kinase (1) RIP kinase (1) Sodium Channel (3) STAT (2) TAM Receptor (1) Tau Protein (1) TGF-beta/Smad (4) TGF-β Receptor (1) TNF Receptor (1) ULK (1) VSV (1) YAP (1)
By Research Areas:	Cancer (30) Cardiovascular Disease (6) Endocrinology (4) Infection (7) Inflammation/Immunology (16) Metabolic Disease (4) Neurological Disease (4)

By Targets:

ADC Antibody (2)

AIM2 (1)

AMPK (1)

Androgen Receptor (1)

Apoptosis (1)

Autophagy (4)

Bacterial (1)

Btk (1)

Calcium Channel (3)

Caspase (1)

CD38 (2)

CDK (2)

Chloride Channel (1)

COX (1)

CXCR (1)

Deubiquitinase (1)

DNA/RNA Synthesis (4)

DYRK (1)

Epigenetic Reader Domain (1)

ERK (1)

FLAP (1)

Fungal (1)

HBV (1)

HDAC (1)

Histone Demethylase (5)

HIV (2)

Isocitrate Dehydrogenase (IDH) (2)

Kinesin (1)

MicroRNA (1)

MyD88 (1)

Neuropeptide Y Receptor (1)

NF-κB (1)

NOD-like Receptor (NLR) (2)

Notch (1)

p38 MAPK (3)

Parasite (3)

Phosphatase (1)

Phosphodiesterase (PDE) (1)

PKA (2)

PKC (3)

Progesterone Receptor (1)

PROTACs (2)

Pyruvate Kinase (1)

RIP kinase (1)

Sodium Channel (3)

STAT (2)

TAM Receptor (1)

Tau Protein (1)

TGF-beta/Smad (4)

TGF-β Receptor (1)

TNF Receptor (1)

ULK (1)

VSV (1)

YAP (1)

By Research Areas:

Cancer (30)

Cardiovascular Disease (6)

Endocrinology (4)

Infection (7)

Inflammation/Immunology (16)

Metabolic Disease (4)

Neurological Disease (4)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: PSMA SNIPERs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-134790

GST-HG131	HBV	Infection
GST-HG131 is a specific inbihitor of hepatitis B virus (HBV) surface antigen, belongs to dihydrobenzopyridooxazepine (DBP) series. GST-HG131 exhibits excellent and specific HBV antigens inhibition with EC₅₀ of 28.2 nM (HBsAg) and 16.0 nM (HBeAg), respectively, but also it is safety for animal .

HY-P10146

Ac-LETD-CHO	Caspase	Cancer
Ac-LETD-CHO is a caspases 8 inhibitor. Ac-LETD-CHO has specific inhibition to casp-8 with an IC₅₀ value of 6.71 nM. Ac-LETD-CHO can be used for the research of anticancer .

HY-W014134

p-APMSF hydrochloride p-Amidinophenylmethylsulfonylfluoride hydrochloride	Others	Others
p-APMSF is an irreversible inhibitor of serinase. p-APMSF has substrate specificity for positively charged side chains of amino acids, lysine, or arginine. p-APMSF can be used to study the irreversible inhibition of trypsin and thrombin .

HY-139852

PLAP-IN-1	Phosphatase	Cancer
PLAP-IN-1 is a potent (IC₅₀ = 32 nM) and selective PLAP inhibitor, with no detectable inhibition of tissue non-specific alkaline phosphatase (TNAP) activity.

HY-149859

HDAC-IN-58	HDAC	Neurological Disease
HDAC-IN-58 is a HDAC inhibitor. HDAC-IN-58 has HDAC6-specific inhibition activity with an IC₅₀ value of 2.06 nM. HDAC-IN-58 can be used for the research of chronic diseases, including neurodegenerative and psychiatric conditions .

HY-114672

MBCQ	Phosphodiesterase (PDE)	Cardiovascular Disease
MBCQ is a potent and selective *cGMP-specific* phosphodiesterase (PDE V; PDE5)** inhibitor with an IC₅₀ of 19 nM. MBCQ lacks inhibitory activity toward other PDE isozymes (all IC₅₀s>100 μM). MBCQ dilates coronary arteries via specific inhibition of cGMP-PDE .

HY-137817

BCH001	DNA/RNA Synthesis	Metabolic Disease
BCH001, a quinoline derivative, is a specific PAPD5 inhibitor. BCH001 restores telomerase activity and telomere length in dyskeratosis congenita (DC) induced pluripotent stem cells. BCH001 shows no inhibition of poly(A)-specific ribonuclease (PARN) or several other canonical and non-canonical polynucleotide polymerases. BCH001 is used to regulate aging .

HY-101370

2-Methylthio-ATP tetrasodium	Others	Metabolic Disease
2-Methylthio-ATP tetrasodium is a non-specific P2-receptor agonist. 2-Methylthio-ATP tetrasodium causes noncompetitive inhibition of ADP-induced human platelet aggregation .

HY-160481

MG-1102	Tau Protein MicroRNA	Neurological Disease
MG-1102 is first-in-class dual binder of monomeric tau and pre-miRNA-146a. MG-1102 shows specific inhibition of miRNA146a with IC₅₀s of 0.21 mM and 0.36 mM specific inhibition of doublelabeled pre-miRNA146a and mono-labeled pre-miRNA146a, respectively. MG-1102 interacts with tau monomers with a K_d of 3.21 mM by surface plasmon resonance (SPR). MG-1102 is a potential multi-target-directed ligands (MTDLs) for Alzheimer’s disease (AD) .

HY-15320

NBI-74330 2 Publications Verification	CXCR	Inflammation/Immunology Endocrinology
NBI-74330 is a potent antagonist for CXCR3, and exhibits potent inhibition of ( ¹²⁵I)CXCL10 and ( ¹²⁵I)CXCL11 specific binding with K_i of 1.5 and 3.2 nM, respectively.

HY-15802

WZ4003 5 Publications Verification	AMPK	Cancer
WZ4003 is the first potent and highly specific NUAK kinase inhibitor with IC₅₀ of 20 nM/100 nM for NUAK1 (ARK5)/NUAK2, without significant inhibition on other 139 kinases.

HY-50937

ST 2825 Maximum Cited Publications 64 Publications Verification	MyD88	Inflammation/Immunology
ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity .

HY-P5881

PKCα (C2-4) inhibitor peptide	PKC	Cardiovascular Disease
PKCα (C2-4) inhibitor peptide is a PKCα‐specific inhibitor peptide that blocks the inhibition of I_Kr by the α_1A‐adrenoreceptor agonist A-61603 (HY-101366) .

HY-155338

SWTX-143	YAP	Cancer
SWTX-143 is a novel covalent YAP/TAZ-TEAD inhibitor that binds to the palmitoylation pocket of all four TEAD isoforms. SWTX-143 causes irreversible and specific inhibition of the transcriptional activity of YAP/TAZ-TEAD and shows antitumor activity .

HY-145721

Mongersen GED-0301	TGF-beta/Smad	Inflammation/Immunology
Mongersen (GED-0301) is a specific and orally active SMAD7 antisense oligonucleotide. Mongersen restores TGF-β1 activity leading to inhibition of inflammatory signals. Mongersen can attenuate Crohn's disease-like experimental colitis in mice .

HY-P9915

Daratumumab 1 Publications Verification Anti-Human CD38, Human Antibody	CD38 ADC Antibody	Inflammation/Immunology Cancer
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .

HY-15838

ID-8 4 Publications Verification	DYRK	Cancer
ID-8 is an inhibitor of *dual-specificity* tyrosine phosphorylation-regulated kinase (DYRK)*. ID-8 sustains embryonic stem cell (ESC) self-renewal and pluripotency. ID-8 enhances Wnt-mediated hESC survival and proliferation via inhibition* of DYRKs .

HY-133118

6RK73 1 Publications Verification	Deubiquitinase	Cancer
6RK73 is a covalent irreversible and specific UCHL1 inhibitor with an IC₅₀ of 0.23 µM. 6RK73 shows almost no inhibition of UCHL3 (IC₅₀=236 µM). 6RK73 specifically inhibit UCHL1 activity in breast cancer .

HY-101122

LX2761
LX2761 is chemically stable and potent inhibitor against sodium-dependent glucose cotransporter 1 (SGLT1) and SGLT2 in vitro with IC₅₀s of 2.2 nM and 2.7nM for hSGLT1 and hSGLT2, but displays specific SGLT1 inhibition in the gastrointestinal (GI) tract .

HY-P9915A

Daratumumab (PBS) 1 Publications Verification Anti-Human CD38, Human Antibody (PBS)	ADC Antibody CD38	Cancer
Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .

HY-156034

NLRP3-IN-19 NLRP3-IN-19	NOD-like Receptor (NLR)	Inflammation/Immunology
JT001 (NLRP3-IN-19) is a potent, specific and orally active inhibitor of NLRP3. JT001 can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 can be used for the research of nonalcoholic steatohepatitis and liver fibrosis .

HY-156034A

JT001 sodium NLRP3-IN-19 sodium	NOD-like Receptor (NLR)	Inflammation/Immunology
JT001 (NLRP3-IN-19) sodium is a potent, specific and orally active inhibitor of NLRP3. JT001 sodium can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 sodium can be used for the research of nonalcoholic steatohepatitis and liver fibrosis .

HY-128348

PK68	RIP kinase	Inflammation/Immunology Cancer
PK68 is a potent orally active and specifical type II inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC₅₀ of ~90 nM, displays inhibition of RIPK1-dependent necroptosis. PK68 powerfully ameliorates TNF-induced systemic inflammatory response syndrome, and can be used for the research of inflammatory disorders and cancer metastasis .

HY-125693

L685818	Fungal	Infection Neurological Disease
L685818 is a specific immunophilin ligand. L685818 was neuroregenerative and non-neuroprotective in primary brain cultures. L685818 protects dopaminergic neurons from toxic inhibition of MPP+ and 6-OHDA, reduces tyrosine hydroxylase (TH) loss, and promotes neuronal process regeneration. L685818 is also an antifungal reagent for Cryptococcus neoformans .

HY-15798

UNC2881	VSV TAM Receptor	Cardiovascular Disease
UNC2881 is an orally active and specific Mer kinase inhibitor, inhibits steady-state Mer kinase phosphorylation with an IC₅₀ value of 22 nM. UNC2881 shows additional inhibition against Axl and Tyro with IC₅₀s of 360 nM and 250 nM, respectively. UNC2881 potently inhibits collagen-induced platelet aggregation, can be used for pathologic thrombosis research .

HY-18754

FR 167653 free base	p38 MAPK Autophagy	Endocrinology
FR 167653 free base, an orally active and selective p38 MAPK inhibitor, is a potent suppressor of TNF-α and IL-1β production via specific inhibition of p38 MAPK activity. FR 167653 free base is effective in treating inflammation, relieving trauma and ischemia-reperfusion injury in vivo .

HY-100421

CPI-455 5 Publications Verification	Histone Demethylase	Cancer
CPI-455 is a specific, pan-KDM5 inhibitor with an IC₅₀ of 10 nM for KDM5A. CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .

HY-P1597

Malantide	PKA PKC	Cancer
Malantide is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide is a highly specific substrate for PKA with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide is also an efficient substrate for PKC with a K_m of 16 μM .

HY-18754A

FR 167653 FR 167653 sulfate	p38 MAPK Autophagy	Endocrinology
FR 167653 (FR 167653 sulfate), an orally active and selective p38 MAPK inhibitor, is a potent suppressor of TNF-α and IL-1β production via specific inhibition of p38 MAPK activity. FR 167653 (FR 167653 sulfate) is effective in treating inflammation, relieving trauma and ischemia-reperfusion injury in vivo .

HY-116788

Lipofermata 2 Publications Verification	Bacterial	Infection
Lipofermata is a fatty acid transport protein 2 (FATP2) inhibitor. Lipofermata shows fatty acid transport inhibition with an IC₅₀ of 4.84 μM in Caco-2 cells. Lipofermata, an analog of spiro-indoline-thadiazole, shows zinc-specific suppression of antibacterial activity. Lipofermata perturbs zinc homeostasis in E. coli K-12 with a MIC of 16 μM .

HY-108645

AL 8697	p38 MAPK Autophagy	Inflammation/Immunology
AL 8697 is a specific and orally active p38α MAPK inhibitor with an IC₅₀ of 6 nM. AL 8697 displays 14-fold greater inhibition of p38α compared to p38β (IC₅₀=82 nM), and 300-fold selectivity for p38α over a panel of 91 kinases. Anti-inflammatory activity .

HY-100421A

CPI-455 hydrochloride	Histone Demethylase	Cancer
CPI-455 hydrochloride is a specific, pan-KDM5 inhibitor with an IC₅₀ of 10 nM for KDM5A. CPI-455 hydrochloride mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .

HY-P1597A

Malantide TFA	PKA PKC	Cancer
Malantide TFA is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide TFA is a highly specific substrate for PKA with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide TFA is also an efficient substrate for PKC with a K_m of 16 μM .

HY-129388A

Pulrodemstat CC-90011; LSD1-IN-7	Histone Demethylase	Cancer
Pulrodemstat (CC-90011) is a potent, selective, reversible and orally active inhibitor of *lysine specific* demethylase-1 (LSD1) with an IC₅₀** of 0.25 nM. Pulrodemstat is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. Pulrodemstat induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .

HY-120072

PF-3450074 3 Publications Verification PF-74	HIV	Infection
PF-3450074 (PF-74) is a specifical inhibitor of HIV-1 capsid protein (CA) and displays a broad-spectrum inhibition of HIV isolates with submicromolar potency (EC₅₀=8-640 nM). PF-3450074 (PF-74) acts at an early stage of HIV-1 infection, inhibits viral replication by directly competing with the binding of CPSF6 and NUP153, and blocks the uncoating, assembly, and the reverse transcription steps of the viral life cycle . CPSF6: nuclear host factors cleavage and polyadenylation specific factor 6; NUP153: nucleoporin 153.

HY-129388B

Pulrodemstat benzenesulfonate 2 Publications Verification CC-90011 benzenesulfonate; LSD1-IN-7 benzenesulfonate	Histone Demethylase	Cancer
CC-90011 benzenesulfonate is a potent, selective, reversible and orally active inhibitor of *lysine specific* demethylase-1 (LSD1) with an IC₅₀** of 0.25 nM. CC-90011 benzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. CC-90011 benzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .

HY-N0822

Shikonin 30+ Cited Publications C.I. 75535; Isoarnebin 4	Chloride Channel Pyruvate Kinase NF-κB TNF Receptor HIV AIM2	Cancer
Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC₅₀ of 6.5 μM . Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit TNF-α and NF-κB pathway . Shikonin decreases exosome secretion through the inhibition of glycolysis . Shikonin inhibits AIM2 inflammasome activation .

HY-108350

MI-2-2	Epigenetic Reader Domain	Cancer
MI-2-2 is a potent menin-MLL inhibitor. MI-2-2 binds to menin with low nanomolar affinity (K_d=22nM) and very effectively disrupts the bivalent protein-protein interaction between menin and MLL. MI-2-2 has specific and very pronounced activity in MLL leukemia cells, including inhibition of cell proliferation, down-regulation of Hoxa9 expression, and differentiation .

HY-129388

Pulrodemstat Methylbenzenesulfonate CC-90011 Methylbenzenesulfonate; LSD1-IN-7 Methylbenzenesulfonate	Histone Demethylase	Cancer
CC-90011 Methylbenzenesulfonate is a potent, selective, reversible and orally active inhibitor of *lysine specific* demethylase-1 (LSD1) with an IC₅₀** of 0.25 nM. CC-90011 Methylbenzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. CC-90011 Methylbenzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .

HY-115570

GW406108X 1 Publications Verification GW108X	Kinesin ULK Autophagy	Cancer
GW406108X is a specific Kif15 (Kinesin-12) inhibitor with an IC₅₀ of 0.82 uM in ATPase assays. GW406108X, a potent autophagy inhibitor, shows ATP competitive inhibition against ULK1 with a pIC₅₀ of 6.37 (427 nM). GW406108X inhibits ULK1 kinase activity and blocks autophagic flux, without affecting the upstream signaling kinases mTORC1 and AMPK .

HY-138215

ADTL-EI1712	ERK	Cancer
ADTL-EI1712 is a potent, orally active, and selective dual-target inhibitor of ERK1 and ERK5, inhibition rates of ERK1/5 at 1 μM are 93.54% and 89.35%, respectively. ADTL-EI1712 can induce regulated cell death, a form of cell death that relies on the activation of genetically encoded machinery, to overcome compensatory mechanism in specific cancer cells in vitro and in vivo .

HY-P0262

Galantide	Neuropeptide Y Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
Galantide, a non-specific galanin receptor antagonist, is a peptide consisting of fragments of galanin and substance P. Galantide recognizes two classes of galanin binding sites (K_D<0.1 nM and ~6 nM) in the rat hypothalamus. Galantide dose dependently (IC₅₀=1.0 nM) antagonizes the galanin-mediated inhibition of the glucose-induced insulin secretion from mouse pancreatic islets. Galantide appears to bind to a single population of SP receptors (K_D~40 nM) .

HY-16712

LDN-214117 1 Publications Verification	TGF-β Receptor	Cancer
LDN-214117 is an orally active ALK2 inhibitor with well-tolerated and good brain penetration. LDN-214117 has a high selectivity and low cytotoxicity for ALK2 with an IC₅₀ value of 24 nM. LDN-214117 also is a specific bone morphogenetic proteins (BMPs) signaling inhibitor and has relatively selective inhibition for BMP6 with an IC₅₀ value of 100 nM. LDN-214117 can be used for the research of fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic pontine glioma (DIPG) ^[2]

HY-N1584

Halofuginone 5+ Cited Publications RU-19110	DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a K_i of 18.3 nM . Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca ²⁺ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .

HY-126675A

AS2863619	CDK STAT	Inflammation/Immunology
AS2863619 enables conversion of antigen-specific effector/memory T cells into Foxp3 ⁺ regulatory T (T_reg) cells for the treatment of various immunological diseases. AS2863619 is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC₅₀s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 inhibition of CDK8/19, which consequently activates the Foxp3 gene .

HY-129284

APHS	COX	Cancer
APHS is a specific and covalent COX-2 inhibitor with neuroprotective effects. COX-2 is a prostaglandin (PG) synthetase overexpressed in colorectal cancer (CRC) and has pleiotropic cancer-promoting effects. APHS modifies COX-2 by acetylating the active site (serine 516), thereby inhibiting prostaglandin production. The neuroprotective activity of APHS is inhibited by prostaglandin E2. APHS also co-inhibits the WNT pathway, an anti-tumor mechanism in addition to COX-2 inhibition .

HY-155408

ALR-27	FLAP	Inflammation/Immunology
ALR-27 is an antagonist of the 5-lipoxygenase (5-LOX) activating protein FLAP and has anti-inflammatory activity. ALR-27 potently inhibits 5-LOX product formation (>80%) in pro-inflammatory M1-MDM, with no significant direct inhibition of 5-LOX. ALR-27 not only reduces prostaglandin and leukotriene (LT) production in neutrophils but also increases the production of specialized prolytic mediators in specific human macrophage phenotypes .

HY-N1584A

Halofuginone hydrobromide 5+ Cited Publications RU-19110 hydrobromide	DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a K_i of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca ²⁺ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .

HY-126675

AS2863619 free base	CDK STAT	Inflammation/Immunology
AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3 ⁺ regulatory T (T_reg) cells for the treatment of various immunological diseases. AS2863619 free base is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC₅₀s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 free base inhibition of CDK8/19, which consequently activates the Foxp3 gene .

HY-139659

ARD-61	PROTACs Androgen Receptor Progesterone Receptor Apoptosis	Cancer
ARD-61 is a highly potent, effective and specific PROTAC androgen receptor (AR) degrader. ARD-61 potently and effectively induces AR and progesterone receptors (PR) degradation in AR+ cancer cell lines. ARD-61 induces apoptosis and effectively induces tumor growth inhibition in the MDA-MB-453 xenograft model in mice . ARD-61 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name	Target	Research Area